Navigation Links
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
Date:8/4/2009

SAN CARLOS, Calif., Aug. 4 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2009.

Net loss for the quarter ended June 30, 2009 was $32.1 million or $0.35 per share, compared to net loss of $33.4 million or $0.36 per share in the second quarter of 2008.

Nektar made improvements to its operating efficiencies as compared to a year ago. Total operating costs and expenses were down 19% to $43.5 million in the second quarter of 2009 as compared to $53.8 million in the second quarter of 2008. For the first half of 2009, total operating costs and expenses were down 28% to $83.5 million as compared to $115.6 million in the first half of 2008.

"In the first half of 2009, we made a strong commitment to advancing our clinical pipeline," stated Howard W. Robin, President and Chief Executive Officer of Nektar. "We completed our Phase 2 clinical program for NKTR-118, and we are poised to report Phase 2 data for NKTR-102 and Phase 1 data for NKTR-105 by year-end. These achievements underscore the strength of Nektar's drug development organization and our successful strategy to focus on developing proprietary drugs with our advanced polymer conjugate technology."

Research and development expense was $24.2 million in the second quarter of 2009 as compared to $33.5 million for the same quarter in 2008. For the first half of 2009, research and development expense was $48.0 million as compared to $70.9 million for the first half of 2008. Included in the $48.0 million of overall research and development expense in the first half of 2009 is approximately $27.4 million of investment in Nektar preclinical and clinical development programs.

Revenue for the three month period ende
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 3, 2015   ... 240 patients respectively Publications in peer reviewed ... Clinical Gastroenterology highlight diagnostic value of confocal laser ... China and across Asia ... (Euronext: MKEA, FR0010609263), inventor of Cellvizio®, the multidisciplinary confocal ...
(Date:3/3/2015)... and Markets ( http://www.researchandmarkets.com/research/x5lz9r/global_poc ) has announced ... 2015-2019" report to their offering. , ... to grow at a CAGR of 8.47 percent over ... IVD devices and tools used for diagnosing diseases in ... these devices helps in the rapid diagnosis of the ...
(Date:3/3/2015)... WAYNE, N.J. , March 3, 2015 ... USA announced today a new, integrated ... new portable solution is now available with a larger ... integrated console mounted system offers a larger viewing area ... console now provides additional space for accessories and storage, ...
Breaking Medicine Technology:Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 2Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 3Two New Publications From Leading Team in China Present Data From Large Clinical Trials Highlighting Advantages of Cellvizio in Diagnosis of Gastric and Esophageal Cancers 4Global POC Diagnostics Market 2015-2019 with Abbott Labs, Alere, Bayer Healthcare, Danaher, F. Hoffmann-La Roche & Johnson & Johnson Dominating 2Konica Minolta Medical Imaging and Shimadzu Medical Systems USA Introduce MobileArt Evolution EFX AeroDR-i with 17" Touch Monitor to Simplify Operation 2Konica Minolta Medical Imaging and Shimadzu Medical Systems USA Introduce MobileArt Evolution EFX AeroDR-i with 17" Touch Monitor to Simplify Operation 3
... Safety and Reduce Health Care CostsBETHESDA, Md., May 7 ... pilot program, contributing data on adverse events associated with ... will be possible to identify best practices that can ... overall costs to the health care system.This pilot hemovigilance ...
... Society Annual Meeting-BALTIMORE, May 7 Arcion Therapeutics, ... that develops pain therapies, today announced the presentation ... significantly reduced pain caused by diabetic neuropathy in ... presented in a poster session on May 8th ...
Cached Medicine Technology:National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 2National Hemovigilance Pilot Program Launches to Track Adverse Events Associated with Blood Transfusion 3Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy 2Arcion Therapeutics' Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy 3
(Date:3/3/2015)... Dan E. Chambers, an experienced Los Angeles criminal ... recently spoke on the radio to give his insights into ... Independent Journal Review radio show “The Right Mics” chose Chambers ... and now as a criminal defense attorney would provide him ... and sentencing of this high-profile case. , During the ...
(Date:3/3/2015)... The report “Alopecia – Pipeline Review, H1 2015? ... Alopecia is the loss of hair. Alopecia areata and ... Causes for alopecia include aging, genetics, illness, chemotherapy, malnutrition ... pattern hair loss, female diffuse hair loss, hairs easily ... focal or diffuse and by the presence or absence ...
(Date:3/3/2015)... Houston, TX (PRWEB) March 03, 2015 ... sponsored by the National Sleep Foundation. The event brings ... the world over. , According to the ... ongoing sleep problems of one form or another. Too ... a greater risk of physical illness and depression, and ...
(Date:3/3/2015)... The combinatorial, multi-gene GeneSight test has ... for patients with depression, and their use of ... genes that comprise the test, according to a ... and Assurex Health, and published online by The ... of the GeneSight Psychotropic test is based on ...
(Date:3/3/2015)... 03, 2015 The North ... to grow from $1,224.6 million to $1,694.6 ... 2014 and 2019. , Browse through the ... market for an analysis of industry trends ... tables and figures., http://www.micromarketmonitor.com/market/north-america-application-delivery-network-adn-7381582251.html , ...
Breaking Medicine News(10 mins):Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 2Health News:Dan E. Chambers Gives Radio Interview Providing Insights into American Sniper Guilty Verdict 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 2Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 3Health News:Alopecia Therapeutics Drugs and Companies Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com 4Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 2Health News:Medicationdiscountcard.com recognizes sleep awareness week with discounts on sleep meds including Ambien, Lunesta, and Sonata 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 2Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 3Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 4Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 5Health News:GeneSight Multi-Gene Combinatorial Pharmacogenomic (CPGx™) Test is More Predictive of Antidepressant Response than Single Gene Tests 6Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 2Health News:The North American Application Delivery Network Market is Estimated to Reach $1,694.6 Million in 2019- A Report By MicroMarket Monitor 3
... 21 countries, reserachers have found that blood pressure levels across ... not go down in all of the populations, but it ... led the World Health Organization MONICA study conducted between 1980s ... did appear to have a cross- population effect. Most importantly, ...
... overseas-trained doctor, Farid Zaer, who has registered himself as ... Queensland, to continue his medical practice.// The doctor has ... accused for wrong diagnosis involving nearly 208 patients. ... as a GP, without any restriction or supervision. Under ...
... African American children deteriorate as they progress through puberty, ... of Alberta//. The levels of insulin, however, remain unchanged ... phase of growth plays a crucial role in determining ... 7-year, Alabama based study was conducted by Dr. Geoff ...
... to tackle the global threat from bird flu, it ... is felt that// it may provide the best help ... up such a system has been published in the ... through co-ordination between such international labs can warn the ...
... pregnancy can reduce the incidence of pregnancy complications, ... by American Journal of Obstetrics and Gynecology. ... blood pressure and proteinuria (high levels of protein ... and legs is usually seen. If left unattended, ...
... In an attempt to spread awareness about AIDS/HIV, the ... the State organized a health awareness program// ('One step ... targeted specifically at barbers. ,The local barbers, ... rally. A special AIDS/HIV awareness session was conducted at ...
Cached Medicine News:Health News:Doctor Accused Of Misdiagnosing 208 Patients: Further Investigation Ordered 2Health News:African American Children More Pone to Develop Diabetes 2
... Test is a rapid in vitro qualitative test ... Virus Type 1 in human whole blood, serum ... by trained personnel in medical facilities, clinical laboratories, ... screening assay capable of providing test results in ...
The Clearblue Easy Digital Ovulation Test detects the surge of "luteinizing hormone in your urine, which usually happens 24 to 36 hours before you ovulate (release an egg). That means youll know the...
... BD Vacutainer® Safety-Lok™ Blood Collection Sets ... without compromising personal safety. The BD ... needles that can be shielded with ... for blood collection and infusion procedures. ...
Simplicity and multi-directional retraction for a broad range of abdominal procedures...
Medicine Products: